Taking Treatment from the Lab to the Clinic: Rishi Singh from Cleveland Clinic

Video

In many, if not most cases, there can be a break in the chain between researchers and the doctors they are developing treatments for. When that divide does not exist it can mean more direct access for doctors and patients to the latest treatments even in the development stages.

In many, if not most cases, there can be a break in the chain between researchers and the doctors they are developing treatments for. When that divide does not exist it can mean more direct access for doctors and patients to the latest treatments even in the development stages.

Rishi Singh, MD, from the Cleveland Clinic considers himself to be fortunate enough to use his clinic as his lab where he is able to help patients with a variety of eye conditions. While his patients present with any number of issues Singh said one of his main areas of focus is the trials of treatments in development for diabetic macular edema and age-related macular degeneration. While there are several medications available for these conditions Singh said they are working to find new options which can last longer and be more effective than those currently on the market.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.